ICIs are also recommended as a first-line treatment for advanced or metastatic NSCLC, either as monotherapy or in combination with chemotherapy or other targeted agents, based on histology, genetic alterations, and level of PD-L1 expression [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]. Here, CD274 is linked to non-small cell lung carcinoma.